Weight loss drug could ease sleep apnoea in people with obesity, study says

Research raises possibility that tirzepatide could become first pharmaceutical treatment for the sleeping disorder

A drug used for type 2 diabetes and weight loss could reduce the severity of obstructive sleep apnoea (OSA) in people with obesity, research suggests, raising the possibility of the first pharmaceutical treatment for the condition.

Tirzepatide, which is made by Eli Lilly and Company, together with other medications such as Wegovy from Novo Nordisk, are part of a new wave of medications sometimes referred to as skinny jabs" because they can result in dramatic weight loss.